Drs. Komrokji and Kuykendall review the evolution of clinical trial endpoints in myelofibrosis studies. They discuss traditional measures of disease control, such as spleen volume reduction and hematologic response, as well as expanded endpoints that reflect the biological and symptomatic aspects of myelofibrosis.
